Medivir AB (MVRBF.PK) said a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases.
In this first in human study, MIV-711 will be administered as single ascending oral doses to healthy volunteers, followed by repeated once daily doses for 7 days, with the aim to explore the safety, tolerability and pharmacokinetics. In addition effect on biomarkers relevant for bone and cartilage degradation will be followed. MIV-711 will also be studied in postmenopausal women following once daily oral dosing for 14 days.
The design of the study will allow Medivir to explore how MIV-711 affects biomarkers known to be relevant for measuring bone and cartilage turnover. It will also provide the company with valuable information regarding potential therapeutic dose levels to be used in future studies. The results from this study are expected in the first quarter of 2013.
Click here to receive FREE breaking news email alerts for MEDIVIR SER B SEK5 and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com